Meeting
2023 ASCO Annual Meeting
Sequential intravenous chemotherapy with drug-eluting bead bronchial arterial chemoembolization for the treatment of stages III and IV lung squamous cell carcinoma: A retrospective controlled clinical study.
Authors
Jianfei Tu
The Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
Jianfei Tu , Lingqiang Lai , Dengke Zhang , Xihui Ying , Li Chen , Jiahao Wu , Jie Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8548)
DOI
10.1200/JCO.2023.41.16_suppl.8548
Abstract #
8548
Poster Bd #
175
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2022 ASCO Annual Meeting
Nivolumab timing as a major survival predictor in patients with stage IV non–small cell lung cancer.
First Author: Abdoulaye Karaboué
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
First Author: Howland E. Crosswell